FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Imfinzi + EV approved in US in bladder cancer
16 November
2026
Perioperative Imfinzi approved in the US in novel regimen with
neoadjuvant enfortumab vedotin for patients with muscle-invasive
bladder cancer
Based on VOLGA Phase III trial data which showed a 49% reduction in
risk of recurrence and a 42% reduction in risk of death, with a
manageable safety profile
Approval
reinforces potential of Imfinzi as an immunotherapy backbone across
muscle-invasive and non-muscle-invasive bladder cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with enfortumab
vedotin (EV) as neoadjuvant treatment, followed by
Imfinzi
monotherapy as adjuvant treatment
after radical cystectomy (surgery to remove the bladder), has been
approved in the US for the treatment of adult patients with
muscle-invasive bladder cancer (MIBC) who are ineligible for or
have refused cisplatin-based chemotherapy.
The approval was granted by the Food and Drug Administration after
securing Priority Review
and was based on results
from the VOLGA Phase III trial which
were presented during a Presidential Symposium at the 2026 European
Society for Medical Oncology (ESMO) Congress and simultaneously
published in The
New England Journal of Medicine.
In 2026, around 16,000 patients will be treated for MIBC in the
United States.1
Approximately one in four patients
with bladder cancer has muscle-invasive disease, where the tumour
invades the muscle wall of the bladder, without distant
metastases.2,3
As many as 50% of patients are
ineligible for cisplatin-based chemotherapy due to impaired renal
function or comorbidities.4,5
The standard treatment for these
patients has historically been radical cystectomy alone, but
despite undergoing this major surgery, patients experience high
rates of recurrence and have a poor prognosis.4-6
Jonathan E. Rosenberg, MD, Chief of the Genitourinary Oncology
Service at the Memorial Sloan Kettering Cancer Center and member of
the VOLGA Steering Committee, said: “This approval brings the
first perioperative immunotherapy regimen where enfortumab vedotin
is administered only in the neoadjuvant setting to patients with
muscle-invasive bladder cancer who are not candidates for
cisplatin-based chemotherapy. The results of VOLGA show a
statistically significant and clinically meaningful improvement in
both event-free and overall survival along with a manageable safety
profile. Based on this, the VOLGA regimen has the potential to
become a new standard of care in this curative-intent
setting.”
Dave Fredrickson, Executive Vice President, Oncology Haematology
Business Unit, AstraZeneca, said: “Today's approval offers a
novel Imfinzi-based regimen that almost halved the risk of disease
recurrence and reduced the risk of death by 42 per cent in the
VOLGA trial, allowing physicians to optimise treatment for patients
in this curative-intent setting. As our third bladder cancer
indication in two years, this approval reinforces
Imfinzi
as an immunotherapy backbone across
muscle-invasive and non-muscle-invasive
disease.”
In the trial, patients were treated with three cycles of
Imfinzi
and EV before radical cystectomy,
followed by nine cycles of Imfinzi adjuvant monotherapy. In a planned interim
analysis, perioperative Imfinzi plus neoadjuvant EV demonstrated a 49% reduction
in the risk of disease progression, recurrence, not undergoing
surgery or death versus radical cystectomy with or without approved
adjuvant treatment (based on an event-free survival [EFS] hazard
ratio [HR] of 0.51; 95% confidence interval [CI] 0.38-0.67;
p<0.0001). Estimated median EFS was not yet reached for
the Imfinzi combination versus 12.1 months for the comparator
arm. An estimated 64% of patients treated with the
Imfinzi
combination remained alive and
event-free at two years compared to 45% in the comparator
arm.
Results from the key secondary endpoint of overall survival (OS)
showed that the Imfinzi combination reduced the risk of death by 42%
compared to the comparator arm (based on an OS HR of 0.58; 95% CI
0.40-0.83; p=0.0027). Estimated median OS was not yet reached for
the Imfinzi combination or comparator arm. An estimated 78% of
patients treated with the Imfinzi combination were alive at two years compared to
69% in the comparator arm.
The safety and tolerability of Imfinzi plus EV was consistent with the known safety
profiles of the individual medicines, with no new safety signals
identified. Grade 3 and 4 adverse events due to any cause occurred
in 64% of patients treated with the Imfinzi combination and 44% of patients in the comparator
arm. Patient-reported quality of life was maintained after surgery
in patients treated with the Imfinzi combination.
Regulatory applications are currently under review in the European
Union (EU), Japan and several other countries based on the results
of the VOLGA trial.
Imfinzi is approved in over 50
countries for patients with cisplatin-eligible MIBC
based on the NIAGARA Phase III trial.
Imfinzi
in combination with Bacillus
Calmette-Guérin (BCG) induction and maintenance therapy is
approved in the US, Japan and other countries for patients with
BCG-naïve, high-risk non-muscle-invasive bladder cancer, based
on the POTOMAC Phase III trial. In July 2026, positive high-level
results from the NILE Phase III trial showed Imfinzi plus chemotherapy demonstrated a statistically
significant and clinically meaningful improvement in OS versus
chemotherapy as 1st-line treatment for patients with PD-L1 high
unresectable, locally advanced or metastatic urothelial
cancer.
Notes
Bladder cancer
Bladder cancer is the 8th most common cancer in the world, with
more than 635,000 cases diagnosed each year.7
The most common type is urothelial
carcinoma, which begins in the urothelial cells of the urinary
tract.8
In 2025, the NIAGARA Phase III trial established a new standard of
care in MIBC by adding perioperative Imfinzi to neoadjuvant cisplatin-based chemotherapy and
radical cystectomy.9
However, up to half of patients are
not eligible to receive cisplatin, and approximately 50% of MIBC
patients who undergo bladder removal surgery experience disease
recurrence. New treatment options that prevent both progression
before surgery and recurrence after surgery are critically needed
in this curative-intent setting.4,6
VOLGA
VOLGA is a Phase III, randomised, open-label, multi-centre global
trial evaluating perioperative Imfinzi with or without Imjudo (tremelimumab) in combination with neoadjuvant EV
as treatment for patients with MIBC undergoing radical cystectomy
who are ineligible for or have refused cisplatin compared to
radical cystectomy with or without approved adjuvant therapy. In
the trial, 695 patients were randomised 1:1:1 to Arm 1 (three
cycles of Imfinzi and EV, plus two cycles of Imjudo prior to surgery, followed by nine cycles
of Imfinzi plus one cycle of Imjudo as adjuvant therapy), Arm 2 (three cycles
of Imfinzi and EV prior to surgery, followed by nine cycles
of Imfinzi adjuvant monotherapy) and Arm 3, the comparator
arm.
The trial was conducted in 182 centres across 25 countries in
Europe, North America, South America and Asia. Its dual primary
endpoints are EFS, defined as the time from randomisation to first
recurrence post-radical cystectomy, first progression in patients
who did not undergo radical cystectomy, failure to undergo radical
cystectomy in patients with residual disease or death due to any
cause, for both experimental arms versus the comparator arm.
Secondary endpoints include OS (Arm 1 vs. Arm 3 and Arm 2 vs. Arm
3), pathologic complete response,
disease-free survival and pathologic downstaging across
both experimental arms.
Imfinzi
Imfinzi (durvalumab) is a human
monoclonal antibody that binds to the PD-L1 protein and blocks the
interaction of PD-L1 with the PD-1 and CD80 proteins, countering
the tumour's immune-evading tactics and releasing the inhibition of
immune responses.
In addition to its bladder cancer indications, Imfinzi is the global standard of care based on OS
in the curative-intent setting of unresectable, Stage III non-small
cell lung cancer (NSCLC) in patients whose disease has not
progressed after chemoradiotherapy (CRT). Additionally,
Imfinzi
is approved as a perioperative
treatment in combination with neoadjuvant chemotherapy in
resectable NSCLC, and in combination with a short course of
Imjudo
and chemotherapy for the treatment of
metastatic NSCLC. Imfinzi is also approved for limited-stage small cell lung
cancer (SCLC) and in combination with chemotherapy (etoposide and
either carboplatin or cisplatin) for the treatment of
extensive-stage SCLC.
Imfinzi is also approved in
combination with chemotherapy in locally advanced or metastatic
biliary tract cancer and in combination with Imjudo in unresectable hepatocellular carcinoma (HCC). It
is also approved as a monotherapy in unresectable HCC in Japan,
China and the EU, and in resectable, early-stage and locally
advanced gastric and gastroesophageal junction cancers in the US,
EU and Japan. Additionally, in April 2026, Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolisation
(TACE) demonstrated
a statistically significant and
clinically meaningful improvement in the primary endpoint of
progression-free survival versus TACE alone for patients with
unresectable HCC eligible for embolisation in the EMERALD-3 Phase
III trial.
Imfinzi in combination with
chemotherapy followed by Imfinzi monotherapy is approved as a 1st-line treatment
for primary advanced or recurrent endometrial cancer (mismatch
repair deficient disease only in the US, EU and China).
Imfinzi
in combination with chemotherapy
followed by Lynparza (olaparib) and Imfinzi is approved for patients with mismatch repair
proficient advanced or recurrent endometrial cancer in the EU and
Japan.
Since the first approval in May 2017, an estimated 600,000 patients
have been treated with Imfinzi. As part of a broad development programme,
Imfinzi
is being tested as a single treatment
and in combinations with other anti-cancer treatments for patients
with NSCLC, bladder cancer, breast cancer, ovarian cancer and
several gastrointestinal cancers.
AstraZeneca in immuno-oncology (IO)
AstraZeneca is a pioneer in introducing the concept of
immunotherapy into dedicated clinical areas of high unmet medical
need. The Company has a comprehensive and diverse IO portfolio and
pipeline anchored in immunotherapies designed to overcome evasion
of the anti-tumour immune response and stimulate the body’s
immune system to attack tumours.
AstraZeneca strives to redefine cancer care and help transform
outcomes for patients with Imfinzi as a monotherapy and in combination
with Imjudo as well as other novel immunotherapies and
modalities. The Company is also investigating next-generation
immunotherapies like bispecific antibodies and therapeutics that
harness different aspects of immunity to target cancer, including
cell therapy and T-cell engagers.
AstraZeneca is pursuing an innovative clinical strategy to bring
IO-based therapies that deliver long-term survival to new settings
across a wide range of cancer types. The Company is focused on
exploring novel combination approaches to help prevent treatment
resistance and drive longer immune responses. With an extensive
clinical programme, the Company also champions the use of IO
treatment in earlier disease stages, where there is the greatest
potential for cure.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging
cancers. It is through persistent innovation that AstraZeneca has
built one of the most diverse portfolios and pipelines in the
industry, with the potential to catalyse changes in the practice of
medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca’s innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com
and follow the Company on Social
Media @AstraZeneca.
Dr. Rosenberg has financial interests related to
AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1.
AstraZeneca
PLC. Investor relations epidemiology spreadsheet. Available at:
https://www.astrazeneca.com/investor-relations.html. Accessed
November 2026.
2.
Burger M, et al. Epidemiology and Risk Factors of
Urothelial Bladder Cancer. Eur Urol. 2013;63(2):234-241.
3.
National
Collaborating Centre for Cancer. Bladder Cancer: Diagnosis and
Management. London: National Institute for Health and Care
Excellence (NICE). Available at:
https://www.ncbi.nlm.nih.gov/books/NBK356289/. Accessed November
2026.
4.
Dash A, et al. Impact of renal impairment on
eligibility for adjuvant cisplatin-based chemotherapy in
patients with urothelial carcinoma of the bladder.
Cancer. 2006;107(3):506-513.
5.
Galsky MD, et al. Treatment of patients with
metastatic urothelial cancer “unfit” for
cisplatin-based chemotherapy. J Clin
Oncol.
2011;29(17):2432-2438.
6.
Holzbeierlein J, et al. Treatment of
Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO
Guideline (2017; Amended 2020, 2024). J Urol. 2024;212(1):3-10.
7.
World
Health Organization. International Agency for Research on Cancer.
Bladder Fact Sheet. Available at:
https://gco.iarc.who.int/media/globocan/factsheets/cancers/30-bladder-fact-sheet.pdf.
Accessed November 2026.
8.
American
Cancer Society. What Is Bladder Cancer? Available at:
https://www.cancer.org/cancer/types/bladder-cancer/about/what-is-bladder-cancer.html.
Accessed November 2026.
9.
AstraZeneca
PLC. Imfinzi approved in the US as first and only perioperative
immunotherapy for patients with muscle-invasive bladder cancer.
Available at:
https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-us-for-bladder-cancer.html.
Accessed November 2026.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 16 November 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|